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Background: The Dialysis Outcomes Quality Initiative (DOQI)-inspired push to create autogenous fistulas has led to a
resurgence of interest in basilic vein transposition as an autogenous access conduit. We reviewed our experience with
autogenous brachial-basilic upper arm transpositions (BTX) to clarify current maturation and patency rates and provide
realistic expectations for a tertiary referral vascular practice.
Methods: We follow an aggressive “all-autogenous” policy with regard to dialysis access and recommend BTX when all
cephalic options are exhausted. Prosthetic grafts are not attempted unless all upper extremity veins are unusable. The
records of all patients undergoing autogenous basilic and brachial vein upper arm transpositions for hemodialysis access
between April 2001 and December 2004 were retrospectively evaluated. Mean follow-up was 10 months (range, 0 to
38 months).
Results: Eighty-seven patients underwent 100 basilic and 3 brachial vein transpositions. Most of the patients were already
receiving hemodialysis (83%), with a mean of 1.1 (range, 0 to 4) previous access attempts. Perioperative complications
included 1 death secondary to amyocardial infarction, 7 hematomas (4 requiring reoperation), and 6 infections (2 requiring
reoperation). Steal syndrome developed in five patients. Maturation rate was 79%. Functional primary and secondary
patency rates were 23% 5% and 47% 6% at 1 year and 11% 5% and 40% 10% at 2 years, respectively (mean SE).
The most common causes of failure for a matured fistula were stenosis within the body of the basilic vein (44%) followed
by central venous outflow stenosis (20%). No preoperative variable, including gender, age, diabetes mellitus, presence of
ipsilateral hemodialysis catheter, number of previous access attempts, maximal or minimal vein diameter, or obesity, had
a significant impact on rate of maturation or long term patency.
Conclusions: In our experience, autogenous brachial-basilic upper arm transposition fistulas have initial maturation rates
that exceed DOQI guidelines, but disappointing short- to medium-term patency rates. Although these outcomes were
obtained within the context of an aggressive all-autogenous policy, the poor durability of these transpositions should
prompt further investigation of current access algorithms. (J Vasc Surg 2005;42:951-6.)The National Kidney Foundation Dialysis Outcomes
Quality Initiative (NKF/DOQI) guidelines were published
in 1997.1 This document emphasized the poor patency and
high need for revision with prosthetic dialysis grafts, rec-
ommended that 50% of all new access procedures be con-
structed with native vein, and proposed a goal of having
40% of patients undergoing dialysis via an autogenous
arteriovenous fistula (AVF).
These recommendations have changed the way many
vascular practices approach hemodialysis access. At our
institution, we have aggressively pursued an “all- autoge-
nous” policy. Routine preoperative duplex vein mapping
and increasing utilization of autogenous brachial-basilic
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doi:10.1016/j.jvs.2005.07.042vein transpositions (BTX) before placement of a forearm
loop graft has helped us create autogenous fistulas in pa-
tients who would have been previously offered a prosthetic
graft based on physical exam alone. Using these techniques,
we have achieved an 80% rate of autologous AVF creation.
Previous reviews of BTX have reported maturation
rates between 60% and 95% and patency rates ranging from
50% to 80% at 2 years.2-5 These reports, however, predate
the current push toward all-autogenous access and may
reflect a more selective patient population. The purpose of
this report was to examine our experience with BTX and
assess current maturation and patency rates in the setting of
an aggressive stance towards creating autogenous fistulas.
METHODS
All patients in this study were evaluated and treated by
surgeons within a university hospital integrated surgery/
interventional radiology practice; five vascular surgeons
participated. Standard protocol at our institution begins
with upper-extremity duplex ultrasound venous mapping
on all patients. Ultrasound venous mapping is performed
with a tourniquet placed around the upper arm, and all
veins seen are checked for size and evidence of scarring and
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undergone multiple failed fistulas, or has a history of exten-
sive catheter use, venography is usually performed to eval-
uate arm veins and rule out central venous obstruction.
Bilateral blood pressures are obtained, but further arterial
evaluation is not routinely performed if pressures are equal
and normal.
The most distal vein 3 mm in diameter is used,
starting with the nondominant arm whenever possible. If
no autogenous forearm or cephalic options exist, a BTX is
performed; prosthetic forearm grafts are reserved for pa-
tients with failed BTX or patients who lack useable basilic
vein. BTXs are carried out in a standard one-stage fashion,
as previously described, with the basilic vein being trans-
posed to a subcutaneous tunnel.6,7
General anesthesia was used in 60% of the cases, the rest
were performed under either local anesthetic with sedation
or regional block. The method of skin closure and drain
placement is dictated by physician preference; approxi-
mately 75% of the time drains are used, and subcuticular
closure is routine.
AVFs are followed closely until maturation, and on an
“as-needed” basis once functional. No routine postopera-
tive surveillance was done after maturation. In general,
fistulas were allowed 6 to 8 weeks to mature before the
initial cannulation.
High venous pressures, cannulation problems, exces-
sive bleeding, or inability to achieve adequate dialysis are
indications for fistulography. Early thrombosis is not cor-
rected unless an obvious problem is thought to be present,
but thrombosis at any time after maturation is treated
aggressively by endovascular or surgical techniques, or
both, as indicated.
A retrospective analysis was performed of consecutive
patients who underwent BTX for hemodialysis access be-
tween January 2001 and December 2004. Patients’ inpa-
tient, clinic, and noninvasive vascular laboratory records
were used for data collection. Death 30 days of the
procedure was considered procedure-related.
Patency was assessed according to Society for Vascular
Surgery guidelines using actuarial life-table estimates.8
Primary patency was defined as the interval that the fistula
was mature and functional (able to be cannulated by two
dialysis needles and achieve flow rates 350 mL/min)
without the need for further intervention. Assisted primary
patency was the interval that the fistula remained patent
with further intervention within the inflow artery, venous
outflow, or central veins to improve function or assist in
maturation. Secondary patency was defined as the entire
interval that the fistula was usable for dialysis. Maturation
was defined as enlargement of the vein to the point at which
cannulation with two needles and dialysis with flows of
350 mL/min was possible.
Statistics were calculated by using StatView statistical
software (SAS Institute, Inc, Cary, NC). Cox proportional
hazards tests were used to determine the significance of
perioperative variables on outcome. Actuarial life table
analysis was used to calculate patency rates. P  .05 wasconsidered significant. When not otherwise noted, results
are reported as mean  standard error.
RESULTS
Eighty-seven patients (44% female) underwent 100
BTX, 96 with adequate follow-up patency data. Complete
demographic data are listed in Table I. In 49% of the
patients, diabetes mellitus was the etiology of their renal
failure. Most patients (83%) were receiving hemodialysis at
the time of their BTX,mainly by tunneled dialysis catheters.
All catheters were jugular: 44% ipsilateral and 56% con-
tralateral. Patients had an average of 1.0  0.1 previous
surgical access attempts before this operation. This repre-
sented the first attempt at dialysis access in 41%.
Sixty-two percent of the BTX were placed on the left
side. Mean largest and smallest diameters of the vein even-
tually used were 4.5 .2 mm (range, 1.9 to 12.6 mm) and
3.2  .1 mm (range, 1.7 to 5.3 mm) respectively. Operative
time averaged 91 4 minutes (range, 43 to 210 minutes).
Fifty-nine percent of procedures were performed on an
ambulatory basis; another 18% were observed overnight
and discharged within 23 hours.
Morbidity was 18%, and 30-day mortality was 1%.
Perioperative complications included seven hematomas
(four requiring operative drainage) and five infections (two
requiring operative drainage). Five patients presented with
significant “steal” symptoms after fistula creation. Two
underwent distal revascularization with interval ligation
pocedures,9 one was treated with proximal arterial angio-
plasty, one fistula was ligated, and one patient refused
intervention. One patient died secondary to a perioperative
myocardial infarction. Twelve other patients died during
follow-up, none directly secondary to their procedure.
Mean follow-up was 9.8 0.9 months (range, 0 to 32
months). Maturation rate was 79%. Primary and secondary
patency rates were 23%  5% and 47%  6% at 1 year and
11%  5% and 40%  10% at 2 years, respectively (Fig 1).
When fistulas that failed to mature were excluded, 2-year
primary and secondary patency rates improved only slightly
to 15%  6% and 55%  12%, respectively (Fig 2). Revi-
sions were necessary in 44% of the fistulas after maturation.
Table I. Demographic data
Female 44%
Age (range) 56  2 years old (9-88)









CAD, Coronary artery disease; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; BMI, body mass index.
All results are reported as mean  SE.Almost all re-interventions were performed percutaneously;
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fistulas that matured and failed (n 25), themost common
cause of failure was stenosis within the body of the vein
itself in 11 (44%), followed by central vein stenosis or
occlusion in five (20%) (Table II).
Cox proportional hazards were used to analyze the
relationship between patient characteristics and outcome.
No preoperative variable, including gender, age, diabetes
mellitus, presence of an ipsilateral hemodialysis catheter,
number of previous access attempts, vein size, or obesity,
had a significant impact on rate of maturation or long-term
patency of the fistulas. Having a postoperative wound
infection or hematoma did not adversely affect patency
Fig 1. Patency in all brachial-basilic transpositions. Standard er-
ror 10 indicated by dashed lines. PP, Primary patency; APP,
assisted primary patency; SP, secondary patency.
Fig 2. Patency inmature fistulas only. Standard error greater than
10 indicated by dashed lines. PP, Primary patency; APP, assisted
primary patency; SP, secondary patency.rates.DISCUSSION
Over the last four decades, advancements in hemo-
dialysis and overall patient care have resulted in signifi-
cantly improved survival in patients with end-stage renal
disease.10 As a result, the prevalence of patients receiving
hemodialysis is rising at approximately 8% per year.11 These
factors, and nationwide concerns regarding problems with
hemodialysis access, prompted the NKF-DOQI authors to
recommend that 50% of all newly created access consist of
autogenous fistulas and that 40% of patients at any given
time undergo dialysis through autogenous AVF. These rec-
ommendations were based on data suggesting that autog-
enous fistulas have significantly better initial patency rates
and require fewer procedures to maintain patency.12-15
This mandate to increase the percentage of autogenous
hemodialysis access prompted a renewed interest in BTX.
Dagher et al6 first described BTX in 1976 and found a
patency rate of 70% at 8 years.16 These results, while
excellent, were obtained in the era before the DOQI-
inspired all-autogenous philosophy adhered to at our insti-
tution. As such, they may represent results in a very care-
fully selected group of patients. We share the concern,
previously commented upon,17 that this more aggressive
attitude toward creation of more autologous AVFs may not
yield these same good results.
In our hands, the maturation rate of BTXs is acceptable
at 76% and is consistent with previously described rates
ranging from 62% to 95%.2,7 Patency, however, is disap-
pointing, even when nonmatured fistulas are excluded (sec-
ondary patency at 2 years is only 50%). Previous reports
describe a wide range of patency rates, ranging from 83% at
2 years2 to 47% at 1 year.5 Some of this discrepancy may be
because of varying definitions of patency and failure to
differentiate between fistulas that are achieving satisfactory
dialysis from those that are merely open.8,15
The mechanism of failure in our matured BTXs is
interesting: 25 failed after maturation, 11 (44%) of which
failed because of stenoses within the body of the vein. It
may be that dissecting the vein out and tunneling it subcu-
taneously predisposes to venous stenosis within the basilic
vein, especially at the transition point between the tunneled
and in situ vein. Alternatively, failure in the body of the vein
may be related to cannulation technique. The proportions
of prosthetic vs autologous access have dramatically shifted
over a very short time span, and the technicians may not yet
have acquired the skill set to successfully and atraumatically
Table II. Etiology of failure
Total number of fistula failures 45
Failed to mature 20
Matured but then failed: 25
Stenosis within vein itself 11
Central venous stenosis 5
Arterial stenosis 2
Ligated (steal, skin breakdown) 2
Unknown 5cannulate and decannulate autogenous fistulas. This hy-
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provement may be possible by better training and increas-
ing experience.
The second most common cause of failure was stenosis
in the central inflow vein at the costoclavicular junction.
Although we currently place no subclavian catheters, many
of our patients have had these in the past, and this remains
a vulnerable area in general, especially given the dramatic
increase in flow produced by this procedure. Arterial steno-
sis only accounted for two of the mature fistula failures, but
it may have played a greater role in the fistulas that did not
mature. A recent study found a 35% incidence of upper-
extremity arterial stenosis, and the argument can be made
to increase the use of noninvasive and invasive arterial
imaging before fistula creation.18
Our data failed to reveal any preoperative variables or
patient characteristics that influenced outcome. One series
demonstrated decreased maturation and patency rates in
patients aged 60 years,2 but data from the United States
Renal Data System showed that transpositions, compared
with direct AVFs, performed worse in younger patients and
better in older.12
These suboptimal patency rates suggest that the best
AV access strategy has yet to be determined. The DOQI
guidelines were based on patency and complication rates
that were published before many institutions were aggres-
sive about creating autogenous fistulas. Although others
describe similarly poor mid-term secondary patency, their
conclusions remain generally strongly in favor of perform-
ing BTX before prosthetic arterial-venous grafts (AVG),2,4
a policy we continue to follow.
Choi et al3 recently compared their institution’s results
with transposed AVFs vs AVGs and simple AVFs, and
concluded that transposed AVFs have a significantly better
long-term patency of 75% at 2 years. However, their trans-
position group included forearm transpositions and upper-
arm cephalic transpositions, which confuse the decision-
making process. A second group compared BTX with
autogenous brachial cephalic fistulas and upper-arm AVGs,
showing equivalent patency but decreased reintervention
and infection rates in the BTX group. Interestingly, BTX
patency at 1 year was 64%.12
We continue to believe that a simple AVF using ce-
phalic vein is the best option, if the anatomy and conduit
are suitable. Our data, however, seem to reopen the ques-
tion of what access is best if the cephalic vein is not usable.
Some authors describe successful placement of an ipsilateral
AVG after failed BTX,4 suggesting the “BTX-first” strategy
to be beneficial. In our experience, however, most patients
went on to catheter-based hemodialysis access after BTX
failure. Reasons included lack of further upper-extremity
venous options and patient refusal of further access at-
tempts. It has been informally suggested that placing a
forearm loop graft before BTX may dilate upper arm veins
and improve outcome of a subsequent upper-arm AVF, but
this has never been systematically studied. Given our re-
sults, it may be useful to re-evaluate the optimal timing of
placement of arteriovenous prosthetic grafts and BTXs in aprospective fashion to help determine the best overall strat-
egy to prolong the duration that an arm is useable for
dialysis.
CONCLUSION
Brachio-basilic vein transpositions can be constructed
with low morbidity and acceptable maturation rates. Purs-
ing the creation of BTX may help achieve the NFK-DOQI
mandate of achieving a 50% rate of autologous fistula
creation; however, in our experience, the need for revision
was high and the intermediate-term patency rates did not
meet expectations. Although this may be due to the selec-
tion of less-optimal patients for BTX, the ultimate goals of
AV access creation are to increase the length of time dura-
ble access is maintained and to minimize the need for
secondary intervention. We believe the optimal timing and
order of access in patients without usable cephalic veins has
not yet been determined.
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Dr Subodh Arora (Washington, DC). First of all, I’d like to
congratulate DrWolford on an excellent presentation. DrWolford
and her colleagues have tried to address a very important issue
related to the increasing use of basilic vein transposition for hemo-
dialysis in the post-DOQI era. They performed a retrospective
review of their experience over a 4-year period, during which time
100 basilic and 3 brachial vein transpositions were performed in
patients who had no usable cephalic vein. Their maturation rate
was 79%, but their primary and secondary patency rates were 24%
and 50% at 1 year and a mere 11% and 37% at 2 years. Twenty-one
transpositions failed to mature, and 26 failed after maturation,
the most common cause of failure was mid-vein stenosis. They
concluded that the maturation rates of basilic vein transposi-
tions are acceptable, but mid- to short-term patency rates are
disappointing.
I have four questions and one comment for the authors.
1. There were seven wound hematomas and six wound infections
in the postoperative period. Did the fistulas in these patients go
on to fail? If so, do you think that prevention of these compli-
cations might have improved your patency rates?
2. Asmost of the failures were due tomid-vein stenosis, could this
have been due to the way the veins were stuck during hemo-
dialysis, mostly in the mid segment?
3. Do you think a more selective policy, rather than an all-
autologous policy, should be the way to go in order to achieve
better patency ratio?
4. Based on your results, what are your recommendations as to
the indications and timing of basilic vein transpositions?
My comment is that in our practice, we prefer to perform a
forearm prosthetic graft if a Cimino or a snuff box fistula are not
feasible and there are no usable forearm veins for some kind of
transposition. Even if the graft lasts for about 6 months, it allows
the upper arm veins to mature, which can then be used for
transposition when the prosthetic graft fails. Do you have any
experience with this strategy?
Once again, I would like to congratulate you on an excellent
presentation and thank you for sending me a well-written manu-
script in a timely fashion. I would also like to thank the Society for
the privilege of discussing this paper.
DrHeatherWolford. In answer to your first question, we did
not look at the influence of wound complications on patency rates.
Subjectively, most of the wound complications happened around
the harvest incision and did not directly involve the tunnel where
the basilic vein was transposed. We do think that cannulation
techniques have an influence on our patency rates. We are dealing
with a large body of dialysis nurses who are much more used to
cannulating prosthetic grafts than autogenous fistulas. This is
definitely a topic that we are interested in looking at more
closely.
In terms of a more selective policy of autogenous fistula
placement, we would love to know which patients will do well with
basilic transpositions and which patients will do less well. Unfor-
tunately, when we looked at our data trying to find a factor or
combination of factors that would influence outcome, nothing wasLastly, you asked if we had any recommendations on ways to
proceed with dialysis access selection. In completing this study, we
were surprised to find that our basilic vein transposition patency
rates were so poor. This is causing us to re-evaluate our current
dialysis access algorithm. We are planning to study in a prospective
fashion whether or not using a prosthetic graft in the forearm—or
any prosthetic graft in the arm—before a basilic transposition may
lead to a longer duration so that the arm itself can be used for
dialysis.
Dr John Blebea (Philadelphia, Penn). I have several questions
concerning the size of the veins.
First, how did you measure your veins? We have recently
examined the effects of arm position, warming, and the use of a
tourniquet in the ultrasound measurements of vein diameter and
have found significant variability. What is the standard protocol in
your vascular laboratory to measure vein diameter and do you
know your accuracy in determining maximal venous size?
Second, why did you choose 3 mm as your size cutoff? Most
surgeons use veins with a diameter of 2.5 mm or larger. However,
in your presentation, you mentioned a range of veins that were
utilized, with some as small as 1.9 mm. If your clinical criteria was
3 mm or greater, why did you use a vein as small as 1.9?
Finally, since vein diameter is one of the most important
criteria in fistula patency, did you stratify your patency results on
the basis of vein size, and could you then establish a cutoff in vein
diameter where there was a significant increase in patency?
Dr Wolford. Our vascular lab has a standard protocol that
involves placing a tourniquet on the upper arm to let the veins
dilate before they do the vein mapping. They do not routinely
warm the veins.
When we reviewed the charts looking at the vein maps, we
reported the largest vein diameter measured by the lab technician
as well as the smallest. Our largest size had a mean of 4.5 mm, but
we also used the basilic vein when there were segments that were
less than 3mm in diameter. We did stratify the results to see if there
was a difference in outcome based on the size. There was no
significant correlation with outcome looking at both largest and
smallest recorded diameter of the vein.
Dr Frank Padberg, Jr (Newark, NJ). Pretty discouraging,
isn’t it? Many of us became enthusiastic about brachial vein trans-
positions many years ago but became much more selective because
our subjective experience was pretty much the same as your report.
However, we have since advocated vein mapping, which brings me
to several questions:
First, you didn’t mention anything about arterial diameter.
Can’t it sometimes have a lot to do with failure to mature?
Second, the pre-op measurement of vein diameter does not
always correlate with the intraoperative measurement, particularly
after you give a general anesthetic. The veins dilate in this situation,
but they’re always larger, never smaller.
Third, did you evaluate the vein for evidence of previous
scarring? I’m sure you didn’t use anything that you knew was
postphlebitic; however, was this a part of your preoperative assess-
ment protocol? Did you find that any were excluded because of
that? And when you looked at your retrospective analysis, could
any of these have been recognized before the operation?
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extremity arteries before performing basilic vein transpositions.
In general, when our basilic transpositions start to fail, the
patients undergo a venogram to see if we can detect a reason for
their failure. At that time, we do look at the brachial artery as
well.
On the ultrasound vein mapping reports, they will comment if
there is scarring or evidence of previous inflammation within the
vein. We also trust our vascular lab technicians’ subjective views of
vein quality.
Dr Padberg. Likewise, in our experience, if scarring or post-
thrombotic changes are visualized, the vein is considered unsuit-able. Wong et al (Eur J Vasc Endovasc Surg 1996:12;207-213)
looked at arterial size. Anything smaller than 1.6 mm was guaran-
teed to fail, whether it was vein or artery.
Dr Karl A. Illig. We used to look at arterial size with
ultrasound, but mostly the radial and ulnar arteries prior to Cimino
AVFs. We have not been religious about doing so recently because
we did not see any clear evidence that the datamade a difference. In
addition, however, these fistulae are obviously based off of a much
larger artery, and we basically assumed that the artery at the
antecubital level would be adequate based on a palpable distal pulse
and normal (or at least symmetrical) forearm pressure. I do agree
that we need to readdress this issue in the future.
